scispace - formally typeset
Search or ask a question
Author

Janine Kimpel

Bio: Janine Kimpel is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Medicine & Vesicular stomatitis virus. The author has an hindex of 15, co-authored 45 publications receiving 609 citations.

Papers published on a yearly basis

Papers
More filters
Journal ArticleDOI
TL;DR: The results indicate that SARS-CoV-2 antigen persistence in infected tissues serves as a basis for post-acute COVID-19, and the concept that viral antigen persistence instigates immune perturbation and post-ACute CO VID-19 requires validation in controlled clinical trials.

112 citations

Journal ArticleDOI
TL;DR: RVSV(GP) offers a considerably improved OV platform that lacks several of the major drawbacks that have limited the clinical potential of this technology to date and escapes humoral immunity, thus, for the first time, allowing repeated systemic OV application without loss of therapeutic efficacy.
Abstract: As cancer treatment tools, oncolytic viruses (OV) have yet to realize what some see as their ultimate clinical potential. In this study, we have engineered a chimeric vesicular stomatitis virus (VSV) that is devoid of its natural neurotoxicity while retaining potent oncolytic activity. The envelope glycoprotein (G) of VSV was replaced with a variant glycoprotein of the lymphocytic choriomeningitis virus (LCMV-GP), creating a replicating therapeutic, rVSV(GP), that is benign in normal brain but can effectively eliminate brain cancer in multiple preclinical tumor models in vivo. Furthermore, it can be safely administered systemically to mice and displays greater potency against a spectrum of human cancer cell lines than current OV candidates. Remarkably, rVSV(GP) escapes humoral immunity, thus, for the first time, allowing repeated systemic OV application without loss of therapeutic efficacy. Taken together, rVSV(GP) offers a considerably improved OV platform that lacks several of the major drawbacks that have limited the clinical potential of this technology to date.

96 citations

Journal ArticleDOI
TL;DR: Professional football training and matches can be carried out safely during the COVID-19 pandemic despite strict hygiene measures including regular PCR testing, according to a medical perspective.
Abstract: Objectives To evaluate the restart of the German Bundesliga (football (soccer)) during the COVID-19 pandemic from a medical perspective. Methods Participants were male professional football players from the two highest German leagues and the officials working closely with them. Our report covers nine match days spread over 9 weeks (May to July 2020). Daily symptom monitoring, PCR testing for SARS-CoV-2 RNA twice weekly, and antibody tests (on two occasions—early during the phase in May 2020 and in the week of the last match) were conducted. Target variables were: (1) onset of typical COVID-19 symptoms, (2) positive PCR results, and (3) IgG seroconversion against SARS-CoV-2. All detected seroconversions were controlled by neutralisation tests. Findings Suspicious symptoms were reported for one player; an immediate additional PCR test as well as all subsequent diagnostic and antibody tests proved negative for coronavirus. Of 1702 regularly tested individuals (1079 players, 623 officials members), 8 players and 4 officials tested positive during one of the first rounds of PCR testing prior to the onset of team training, 2 players during the third round. No further positive results occurred during the remainder of the season. 694 players and 291 officials provided two serum samples for antibody testing. Nine players converted from negative/borderline to positive (without symptoms); two players who initially tested positive tested negative at the end of the season. 22 players remained seropositive throughout the season. None of the seroconversions was confirmed in the neutralisation test. Conclusion Professional football training and matches can be carried out safely during the COVID-19 pandemic. This requires strict hygiene measures including regular PCR testing.

89 citations

Journal ArticleDOI
28 Dec 2020-Vaccine
TL;DR: In this paper, the authors compared four different SARS-CoV-2 neutralization assays using the same set of patient samples and found that the results obtained with different assays are comparable.

80 citations


Cited by
More filters
10 Mar 2020

2,024 citations

Journal ArticleDOI
29 Apr 2021-Cell
TL;DR: In this article, the authors evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2.

1,109 citations

Journal ArticleDOI
01 Jan 2022-Cell
TL;DR: In this article , the authors measured the neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.1.1/B.COV2.

787 citations

Journal ArticleDOI
29 Apr 2021-Cell
TL;DR: In this article, the authors show that SARS-CoV-2/COVID-19 variants B.1.7 (UK), B.351 (South Africa), and P.1 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies.

754 citations

Journal ArticleDOI
TL;DR: Methods to overcome the blood-brain tumor barrier barrier (BBTB) are provided, including osmotic blood- brain barrier disruption (BBBD), bradykinin receptor-mediated BBTB opening, inhibition of multidrug efflux transporters, receptor- mediated transport systems and physiological circumvention of the BBTB.

655 citations